![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/08\/4000-logo-4-2.jpg\"){kind=logo}
<\/p>\n<\/p>\n
PCI Biotech’s second quarter and first half 2020 interim report will be released on 26 August 2020 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com.<\/p>\n
A results presentation (in English) will be held through a webcast at 08.30 CEST the same day. The webcast can be accessed through www.pcibiotech.com and it will be possible to post questions through the webcast console.<\/p>\n
For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757<\/p>\n
About PCI Biotech <\/strong> Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem<\/em><\/strong> consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc<\/em><\/strong> applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc<\/em><\/strong> utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.<\/p>\n For further information, please visit: www.pcibiotech.com Tags:<\/b> Ronny Skuggedal, CFO
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem<\/em><\/strong> (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc<\/em><\/strong> (T-cell induction technology for therapeutic vaccination), and fimaNAc <\/em><\/strong>(nucleic acid therapeutics delivery).<\/p>\n
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo <\/p>\nSee Campaign: <\/strong>http:\/\/http:\/\/www.pcibiotech.com<\/a>
Contact Information:<\/b>
Ronny Skuggedal, CFO
\nEmail: rs@pcibiotech.no
\nMobile: +47 9400 5757<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\nEmail: rs@pcibiotech.no
\nMobile: +47 9400 5757<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"PCI Biotech’s second quarter and first half 2020 interim report will be released on 26 August 2020 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com. A results presentation (in English) will be held through a webcast at 08.30 CEST the same day. The … Continue reading PCI Biotech: Invitation to second quarter and first half 2020 results presentation<\/span><\/a> Continue Reading